KR102717616B1 - PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도 - Google Patents

PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도 Download PDF

Info

Publication number
KR102717616B1
KR102717616B1 KR1020237033761A KR20237033761A KR102717616B1 KR 102717616 B1 KR102717616 B1 KR 102717616B1 KR 1020237033761 A KR1020237033761 A KR 1020237033761A KR 20237033761 A KR20237033761 A KR 20237033761A KR 102717616 B1 KR102717616 B1 KR 102717616B1
Authority
KR
South Korea
Prior art keywords
mmol
chloro
methyl
pyrazolo
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237033761A
Other languages
English (en)
Korean (ko)
Other versions
KR20230145517A (ko
Inventor
윈-륭 리
원칭 야오
앤드류 피. 콤스
에디 더블유. 웨
쓩 메이
원위 주
조셉 글렌
주니어 토마스 피. 마두스쾌이
리차드 비. 스파크스
브렌트 두티
춘흉 허
Original Assignee
인사이트 홀딩스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인사이트 홀딩스 코포레이션 filed Critical 인사이트 홀딩스 코포레이션
Priority to KR1020247033698A priority Critical patent/KR20240152422A/ko
Publication of KR20230145517A publication Critical patent/KR20230145517A/ko
Application granted granted Critical
Publication of KR102717616B1 publication Critical patent/KR102717616B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237033761A 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도 Active KR102717616B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247033698A KR20240152422A (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01
US61/771,480 2013-03-01
PCT/US2014/019372 WO2014134426A1 (en) 2013-03-01 2014-02-28 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
KR1020227035039A KR102586858B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035039A Division KR102586858B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033698A Division KR20240152422A (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도

Publications (2)

Publication Number Publication Date
KR20230145517A KR20230145517A (ko) 2023-10-17
KR102717616B1 true KR102717616B1 (ko) 2024-10-16

Family

ID=50288319

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020237033761A Active KR102717616B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020157027010A Active KR102298150B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020247033698A Pending KR20240152422A (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020217027697A Active KR102454308B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020227035039A Active KR102586858B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020157027010A Active KR102298150B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020247033698A Pending KR20240152422A (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020217027697A Active KR102454308B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도
KR1020227035039A Active KR102586858B1 (ko) 2013-03-01 2014-02-28 PI3Kδ 관련 장애의 치료를 위한 피라졸로피리미딘 유도체의 용도

Country Status (32)

Country Link
US (6) US9932341B2 (enExample)
EP (3) EP3632442B1 (enExample)
JP (5) JP6545106B2 (enExample)
KR (5) KR102717616B1 (enExample)
CN (2) CN105120871B (enExample)
AR (1) AR094964A1 (enExample)
AU (5) AU2014223257B2 (enExample)
BR (1) BR112015020941A2 (enExample)
CA (1) CA2901993C (enExample)
CL (1) CL2015002442A1 (enExample)
CR (1) CR20150472A (enExample)
CY (1) CY1122712T1 (enExample)
DK (1) DK2961410T3 (enExample)
EA (2) EA201591612A1 (enExample)
ES (2) ES2774436T3 (enExample)
HR (1) HRP20200263T1 (enExample)
HU (1) HUE047719T2 (enExample)
IL (6) IL301180A (enExample)
LT (1) LT2961410T (enExample)
MX (2) MX367713B (enExample)
MY (1) MY177875A (enExample)
PE (1) PE20151996A1 (enExample)
PH (3) PH12021552233A1 (enExample)
PL (1) PL2961410T3 (enExample)
PT (1) PT2961410T (enExample)
RS (1) RS59958B1 (enExample)
SG (3) SG10201912275YA (enExample)
SI (1) SI2961410T1 (enExample)
SM (1) SMT202000043T1 (enExample)
TW (5) TWI736135B (enExample)
UA (1) UA119641C2 (enExample)
WO (1) WO2014134426A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
TWI736135B (zh) * 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
KR20240153401A (ko) 2014-04-08 2024-10-22 인사이트 홀딩스 코포레이션 Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
DK3831833T3 (da) * 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
KR102514814B1 (ko) 2016-03-31 2023-03-27 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
EP3679042B1 (en) * 2017-09-08 2023-03-01 BeiGene, Ltd. IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3737684B1 (en) * 2018-01-10 2022-11-16 Idorsia Pharmaceuticals Ltd 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
JP2023551519A (ja) 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
WO2023114369A2 (en) 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of pi3k-delta inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
CN1960988B (zh) 2004-06-10 2012-01-25 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
AR060316A1 (es) 2006-01-17 2008-06-11 Vertex Pharma Azaindoles de utilidad como inhibidores de janus quinasas
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
US20110105500A1 (en) 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
MX2011010631A (es) 2009-04-09 2012-01-20 Oncothyreon Inc Metodos y composiciones de inhibidores de quinasa pi-3 para tratar fibrosis.
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI736135B (zh) * 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015191677A1 (en) * 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
DK3831833T3 (da) * 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
WO2020102150A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors

Also Published As

Publication number Publication date
MX2015011273A (es) 2015-12-03
CA2901993A1 (en) 2014-09-04
LT2961410T (lt) 2020-02-10
WO2014134426A1 (en) 2014-09-04
US20210332059A1 (en) 2021-10-28
AR094964A1 (es) 2015-09-09
EP3632442B1 (en) 2023-04-05
TWI657090B (zh) 2019-04-21
KR20240152422A (ko) 2024-10-21
AU2022218495B2 (en) 2024-10-03
CN109010343A (zh) 2018-12-18
AU2022218495A1 (en) 2022-09-08
IL240784A0 (en) 2015-10-29
JP2025003975A (ja) 2025-01-14
CN105120871A (zh) 2015-12-02
UA119641C2 (uk) 2019-07-25
IL267853B (en) 2020-03-31
AU2024287194A1 (en) 2025-01-23
EP2961410B1 (en) 2019-12-11
KR102298150B1 (ko) 2021-09-07
US20220106318A1 (en) 2022-04-07
EA202192151A1 (ru) 2021-12-31
AU2014223257B2 (en) 2018-11-29
SMT202000043T1 (it) 2020-03-13
US20190040067A1 (en) 2019-02-07
AU2018264053A1 (en) 2018-12-06
EP3632442A1 (en) 2020-04-08
EP4233869A2 (en) 2023-08-30
ES2774436T3 (es) 2020-07-21
AU2014223257A1 (en) 2015-09-24
US12152033B2 (en) 2024-11-26
KR20210110409A (ko) 2021-09-07
PE20151996A1 (es) 2016-01-13
CY1122712T1 (el) 2021-03-12
CA2901993C (en) 2023-03-07
EP4233869A3 (en) 2023-11-01
JP6776399B2 (ja) 2020-10-28
JP2019142941A (ja) 2019-08-29
PH12019501321A1 (en) 2020-10-12
IL311666A (en) 2024-05-01
TW202214254A (zh) 2022-04-16
ES2945212T3 (es) 2023-06-29
HK1221398A1 (en) 2017-06-02
AU2018264053B2 (en) 2020-08-20
IL267853A (en) 2019-09-26
TWI687220B (zh) 2020-03-11
TW201444846A (zh) 2014-12-01
IL240784B (en) 2020-06-30
KR20150135327A (ko) 2015-12-02
PH12021552233A1 (en) 2022-07-18
TW201929860A (zh) 2019-08-01
TWI841376B (zh) 2024-05-01
KR20230145517A (ko) 2023-10-17
PH12015501920B1 (en) 2016-01-18
JP2021020914A (ja) 2021-02-18
RS59958B1 (sr) 2020-03-31
TWI736135B (zh) 2021-08-11
HRP20200263T1 (hr) 2020-05-29
KR20220143146A (ko) 2022-10-24
CN105120871B (zh) 2018-08-10
TW202333734A (zh) 2023-09-01
IL274771A (en) 2020-07-30
PT2961410T (pt) 2020-03-02
PL2961410T3 (pl) 2020-05-18
MX2019010422A (es) 2019-10-15
MY177875A (en) 2020-09-24
AU2020210278A1 (en) 2020-08-20
JP2023036609A (ja) 2023-03-14
SG10201707130UA (en) 2017-10-30
CL2015002442A1 (es) 2016-02-05
MX367713B (es) 2019-09-03
TW202019428A (zh) 2020-06-01
SG11201506654UA (en) 2015-09-29
US20140249132A1 (en) 2014-09-04
CR20150472A (es) 2016-01-04
JP2016510035A (ja) 2016-04-04
JP6545106B2 (ja) 2019-07-17
JP7556010B2 (ja) 2024-09-25
IL301180A (en) 2023-05-01
EP2961410A1 (en) 2016-01-06
DK2961410T3 (da) 2020-02-17
PH12019501321B1 (en) 2020-10-12
BR112015020941A2 (pt) 2017-07-18
US9932341B2 (en) 2018-04-03
PH12015501920A1 (en) 2016-01-18
IL283943A (en) 2021-07-29
JP7189185B2 (ja) 2022-12-13
SI2961410T1 (sl) 2020-03-31
EA201591612A1 (ru) 2016-05-31
AU2020210278B2 (en) 2022-05-26
IL283943B1 (en) 2023-04-01
KR102586858B1 (ko) 2023-10-11
HUE047719T2 (hu) 2020-05-28
IL283943B2 (en) 2023-08-01
US20250289823A1 (en) 2025-09-18
KR102454308B1 (ko) 2022-10-14
SG10201912275YA (en) 2020-04-29
US20220119393A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US12152033B2 (en) Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders
JP6266743B2 (ja) Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン
HK40098131A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HK40027828A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HK1221398B (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601